UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review of trials currently testing treatment and prevention of COVID-19

Clinical microbiology and infection, 2020-08, Vol.26 (8), p.988-998

2020

Volltextzugriff (PDF)

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

CPT: pharmacometrics and systems pharmacology, 2017-02, Vol.6 (2), p.87-109

2017

Volltextzugriff (PDF)

The Use of Model-Based Tumor-Size Metrics to Predict Survival

Clinical pharmacology and therapeutics, 2014-08, Vol.96 (2), p.133-135

2014

Volltextzugriff (PDF)

Two levels of specialization in bacteraemic Escherichia coli strains revealed by their comparison with commensal strains

Epidemiology and infection, 2017-04, Vol.145 (5), p.872-882

2017

Volltextzugriff (PDF)

Influence of Alpha-1 Glycoprotein Acid Concentrations and Variants on Atazanavir Pharmacokinetics in HIV-Infected Patients Included in the ANRS 107 Trial

Antimicrobial Agents and Chemotherapy, 2010-02, Vol.54 (2), p.614-619

2010

Volltextzugriff (PDF)

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features

Clinical microbiology and infection, 2011-04, Vol.17 (4), p.557-565

2011

Volltextzugriff (PDF)

High acquisition rate of extended-spectrum β-lactamase-producing Enterobacteriaceae among French military personnel on mission abroad, without evidence of inter-individual transmission

Clinical microbiology and infection, 2019-05, Vol.25 (5), p.631.e1-631.e9

2019

Volltextzugriff (PDF)

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients

Clinical pharmacology and therapeutics, 2012-11, Vol.92 (5), p.575-583

2012

Volltextzugriff (PDF)

Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia

European journal of clinical pharmacology, 2015-01, Vol.71 (1), p.75-83

2015

Volltextzugriff (PDF)

Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?

British journal of cancer, 2013-09, Vol.109 (5), p.1147-1156

2013

Volltextzugriff (PDF)

Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa

CPT: pharmacometrics and systems pharmacology, 2014-12, Vol.3 (12), p.1-4

Mentré, F

2014

Volltextzugriff (PDF)

The Emergence of Linezolid Resistance among Enterococci in Intestinal Microbiota of Treated Patients Is Unrelated to Individual Pharmacokinetic Characteristics

Antimicrobial agents and chemotherapy, 2014-05, Vol.58 (5), p.2681-2687

2014

Volltextzugriff (PDF)

Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-Effects Modeling

Clinical pharmacology and therapeutics, 2012-02, Vol.91 (2), p.234-242

2012

Volltextzugriff (PDF)

Determinants of macroscopic anal cancer and precancerous lesions in 1206 HIV-infected screened patients

Colorectal disease, 2016-10, Vol.18 (10), p.997-1004

2016

Volltextzugriff (PDF)

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

British journal of clinical pharmacology, 2007-11, Vol.64 (5), p.603-612

2007

Volltextzugriff (PDF)

Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses

Clinical microbiology and infection, 2014-12, Vol.20 (12), p.O1035-O1041

2014

Volltextzugriff (PDF)

Joint Population Pharmacokinetic Analysis of Zidovudine, Lamivudine, and Their Active Intracellular Metabolites in HIV Patients

Antimicrobial Agents and Chemotherapy, 2011-07, Vol.55 (7), p.3423-3431

2011

Volltextzugriff (PDF)

The ISoP Standards and Best Practices Committee

Clinical pharmacology and therapeutics, 2014-06, Vol.95 (6), p.581-582

2014

Volltextzugriff (PDF)

A Pharmacokinetic-Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response

Clinical pharmacology and therapeutics, 2014-11, Vol.96 (5), p.599-608

2014

Volltextzugriff (PDF)

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

CPT: pharmacometrics and systems pharmacology, 2013-06, Vol.2 (6), p.1-2

2013

Volltextzugriff (PDF)

Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008–2009 winter

Clinical microbiology and infection, 2013-02, Vol.19 (2), p.196-203

2013

Volltextzugriff (PDF)

CO1.2 - La randomisation distributive : un nouveau schéma d'essai pour l'évaluation simultanée d'interventions

Journal of Epidemiology and Population Health, 2024-05, Vol.72

2024

Volltextzugriff (PDF)

CO1.2 - La randomisation distributive : un nouveau schéma d'essai pour l'évaluation simultanée d'interventions

Journal of Epidemiology and Population Health, 2024-05, Vol.72, p.202401, Article 202401

2024

Volltextzugriff (PDF)

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study

The European respiratory journal, 2012-03, Vol.39 (3), p.772-775

2012

Volltextzugriff (PDF)

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

CPT: pharmacometrics and systems pharmacology, 2014-04, Vol.3 (4), p.1-9

2014

Volltextzugriff (PDF)

1 – 25 von 225

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals 2020 Medicine

KollektionTaylor & Francis:Master (3349 titles)

ThemaPhysical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(200)
Mit Volltextzugriff
(198)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Review of trials currently testing treatment and prevention of COVID-19

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

The Use of Model-Based Tumor-Size Metrics to Predict Survival

Two levels of specialization in bacteraemic Escherichia coli strains revealed by their comparison with commensal strains

Influence of Alpha-1 Glycoprotein Acid Concentrations and Variants on Atazanavir Pharmacokinetics in HIV-Infected Patients Included in the ANRS 107 Trial

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features

High acquisition rate of extended-spectrum β-lactamase-producing Enterobacteriaceae among French military personnel on mission abroad, without evidence of inter-individual transmission

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients

Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia

Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?

Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa

The Emergence of Linezolid Resistance among Enterococci in Intestinal Microbiota of Treated Patients Is Unrelated to Individual Pharmacokinetic Characteristics

Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-Effects Modeling

Determinants of macroscopic anal cancer and precancerous lesions in 1206 HIV-infected screened patients

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses

Joint Population Pharmacokinetic Analysis of Zidovudine, Lamivudine, and Their Active Intracellular Metabolites in HIV Patients

The ISoP Standards and Best Practices Committee

A Pharmacokinetic-Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008–2009 winter

CO1.2 - La randomisation distributive : un nouveau schéma d'essai pour l'évaluation simultanée d'interventions

CO1.2 - La randomisation distributive : un nouveau schéma d'essai pour l'évaluation simultanée d'interventions

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

Aktive Filter

Suchergebnisse filtern